Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial [Yahoo! Finance]
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
Gilead Sciences (NASDAQ:GILD) had its "outperform" rating reaffirmed by analysts at Wolfe Research.
Is Earlier Yescarta Use in Lymphoma Altering The Investment Case For Gilead Sciences (GILD)? [Yahoo! Finance]
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Morgan Stanley from $147.00 to $151.00. They now have an "overweight" rating on the stock.